CompletedPhase 4

The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles

Egypt600 participantsStarted 2017-07-06

Plain-language summary

The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Females undergoing Intra-Cytoplasmic Sperm Injection (ICSI) cycles * Age between 20 and 40 years Exclusion Criteria: * Females who have high response (estradiol at time of ovulation trigger is \> 5000 pg/ml or more than 15 oocytes are retrieved)

What they're measuring

Live birth rate

Timeframe: This outcome will be calculated 2 years after enrollment of the first patient in the study

Trial details

NCT IDNCT03209687

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-15

View on ClinicalTrials.gov More Infertility trials